(Yicai) Feb. 21 -- Huiyu Pharmaceutical said Egypt’s drugs regulator has approved two of its cancer drugs and one osteoporosis treatment for use in the North African country.

The Egyptian Drug Authority approved Huiyu‘s Docetaxel, Bendamustine, and Zoledronic Acid for marketing, the Neijiang-based firm announced late yesterday.

Docetaxel injections are used to treat locally advanced or metastatic breast cancer and non-small cell lung cancer and are somewhat effective with illnesses such as head and neck cancer, pancreatic cancer, and gastric cancer, Huiyu noted.

The drug was previously approved for marketing in 32 countries and regions, including China, the United Kingdom, and Germany, and registration applications have been submitted for nine others, including Hong Kong and Libya, it added.

Bendamustine hydrochloride injections, a treatment for chronic lymphocytic leukemia and multiple myeloma, had already won marketing approval in 14 countries and regions such as China, the UK, the United Arab Emirates, Canada, and South Africa.

Zoledronic Acid injections for osteoporosis have been given the go-ahead in 15 countries and regions, including China, the UK, Singapore, and Malaysia.

Huiyu’s drug for treating chronic infections was also green-lighted for marketing in the UK on Feb. 18.

The company strived to expand its overseas business last year after revenue shrank at home. Overseas income rose 24 percent to CNY40.2 million (USD5.6 million) in the first six months of 2023 from a year earlier and accounted for 8.9 percent of its total, up from 3.9 percent in the whole of 2022. Revenue from its China business nearly halved to CNY410 million (USD57.1 million).

Shares of Huiyu [SHA: 688553] rose 1.2 percent to close at CNY12.23 (USD1.70) today. The benchmark Shanghai Composite Index gained almost 1 percent.

Editor: Martin Kadiev